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Background: The human 'protective protein' (HPP)
forms a multi-enzyme complex with 3-galactosidase and
neuraminidase in the lysosomes, protecting these two gly-
cosidases from degradation. In humans, deficiency of HPP
leads to the lysosomal storage disease galactosialidosis.
Proteolytic cleavage of the precursor form of HPP
involves removal of a 2 kDa excision peptide and results
in a carboxypeptidase activity. The physiological rel-
evance of this activity is, as yet, unknown.
Results: The crystal structure of the 108 kDa dimer of
the precursor HPP has been elucidated by making exten-
sive use of twofold density averaging. The monomer con-
sists of a 'core' domain and a 'cap' domain. Comparison
with the distantly related wheat serine carboxypeptidase
dimer shows that the two subunits in the HPP dimer dif-
fer by 150 in mutual orientation. Also, the helical sub-
domain forming part of the cap domains is very different.
In addition, the HPP precursor cap domain contains a
'maturation' subdomain of 49 residues which fills the
active-site cleft. Merely removing the 'excision' peptide
located in the maturation subdomain does not render the
catalytic triad solvent accessible.
Conclusions: The activation mechanism of HPP is
unique among proteases with known structure. It differs
from the serine proteases in that the active site is preformed
in the zymogen, but is blocked by a maturation sub-
domain. In contrast to the zinc metalloproteases and aspar-
tic proteases, the chain segment physically rendering the
catalytic triad solvent inaccessible in HPP is not cleaved off
to form the active enzyme. The activation must be a
multi-step process involving removal of the excision pep-
tide and major conformational changes of the maturation
subdomain, whereas the conformation of the enzymatic
machinery is probably almost, or completely, unaffected.
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Introduction
A defect in the human 'protective protein' (HPP), which
is thought to be identical to cathepsin A and thus is also
known as protective protein/cathepsin A (PPCA), has
been identified as the primary genetic lesion underlying
galactosialidosis [1], a lysosomal storage disease inherited
as an autosomal recessive trait. Patients with this disorder
are biochemically diagnosed as having drastically reduced
3-galactosidase and neuraminidase activities in the
lysosomes [2-4]. Three clinical phenotypes of this syn-
drome are distinguished according to age of onset: an
'early infantile', a 'late infantile' and a 'juvenile/adult'
form. Slightly different spectra of symptoms are observed
accompanying each clinical form. These include skeletal
dysplasia, dysmorphism, progressive neurological deterio-
ration, reduced life expectancy, and in some cases mental
retardation, as well as impairment of cardiac and kidney
function (for reviews, see [5,6]).
The molecular basis of galactosialidosis has been shown
to be more complicated than GM-gangliosidosis,
Morquio B and sialidosis, syndromes in which either
,3-galactosidase or neuraminidase activities are deficient
(reviewed in [7,8]). In cultured galactosialidosis fibro-
blasts, -galactosidase appears to. be produced at normal
levels [1,9], but its half-life is reduced from ten days to
less than one day [10]. Loss of the -galactosidase activity
is due to rapid degradation of the enzyme upon arrival in
the lysosomal compartment [11] and it is likely that neu-
raminidase suffers the same fate. These findings have led
researchers to propose, and subsequently demonstrate, a
deficiency in galactosialidosis patients of a third lysosomal
protein, HPP, which serves to stabilize -galactosidase
and neuraminidase in a multi-enzyme complex [1,9].
Upon uptake of HPP from the culture medium by
galactosialidosis fibroblasts, both -galactosidase and
neuraminidase activities are indeed restored [1].
HPP is synthesized as a 542 amino acid precursor with a
molecular weight of 54 kDa [12] and dimerizes soon
after synthesis in the endoplasmic reticulum [13]. The
sequence contains two glycosylation sites (Asnll7 and
Asn305) and nine cysteines. After transport to the acidic
endosomal/lysosomal compartments, the precursor
undergoes a protease-mediated maturation process. A
polypeptide of approximately 2 kDa, called the 'excision'
peptide is removed from the protein yielding a 32 kDa
and a 20 kDa chain held together by disulfide bridges
[14]. Amino acid sequencing of tryptic peptides from
mature HPP isolated from placenta has shown that
residue Arg284 is still present in the 32 kDa chain after
maturation [12]; while Met299 is the first residue in the
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20 kDa chain [12,15]. The excision peptide thus com-
prises, at most, residues Met285-Arg298. The matura-
tion event can be mimicked in vitro by limited proteolysis
with trypsin, probably cleaving at sites Arg284, Arg298 as
well as Arg292 [14].
Surprisingly, HPP has approximately 30% sequence iden-
tity to the wheat and yeast serine carboxypeptidases
(abbreviated CPW and CPY respectively), both members
of the hydrolase fold family [16-18]. The serine car-
boxypeptidases have peptidase activity at acidic pH (pH
4.5-5.5) as well as deamidase and esterase activities at pH
7 (reviewed in [19,20]). Mutagenesis studies and enzy-
matic assays have revealed that HPP, but only its mature
form, possesses serine carboxypeptidase activity. Based on
sequence alignments with serine carboxypeptidases, the
catalytic triad in HPP has been proposed to be formed by
the residues Ser150, His429 and Asp372 [12].
HPP appears to be a multi-functional lysosomal enzyme.
It occurs in lysosomes in a high molecular weight
multi-enzyme complex with -galactosidase and neu-
raminidase [21-26], but a large amount of lysosomal
HPP is found in an unassociated dimeric form as well
[27]. Although the exact physiological substrate(s) of
HPP are not known, there is evidence that HPP may be
secreted to participate extracellularly in the deactivation
of selected bio-active peptides such as endothelin I
[15,28-31]. While loss of the protective capacity of HPP
is directly linked to galactosialidosis, it is unclear to what
extent loss of the enzymatic activity contributes to the
clinical phenotype. Given its pleiotropic and distinct
functions, as well as the capacity to be secreted and
taken up by different cell types, HPP may have a func-
tion outside the multi-enzyme complex and possibly
outside the lysosomes as well.
This paper describes the crystal structure determination
of the precursor form of HPP by a combination of mol-
ecular replacement and twofold density averaging. The
structure presented here is the first of an enzyme associ-
ated with a human lysosomal storage disease, and the
third human lysosomal enzyme structure determined
after cathepsin B [32] and cathepsin D [33,34].
Results and discussion
The HPP precursor monomer
The HPP precursor monomer has dimensions of
60 Ax50 Ax 70 A and is present as a dimer in our crys-
tal structure. The monomer contains approximately
20% 13 structure and 30% helical structure. The protein
fold can be divided into two domains: a 'core' domain,
as commonly found in members of the hydrolase fold
family [18] and a 'cap' domain (Fig. la). The core
domain, comprising residues 1-182 as well as 303-452,
contains a central ten-stranded 13 sheet. An additional
ten ot helices and two small strands occur on both
sides of the central sheet. The cap domain can be
divided into a 'helical' subdomain consisting of three
cx helices (residues 183-253) and a 'maturation' sub-
domain consisting of a three-stranded mixed 13 sheet
(residues 254-302). A Cot trace of the monomer is
shown in Figure lb.
Fig. 1. (a) Schematic ribbon diagram of the HPP monomer (monomer 1). The 'core' domain is shown in yellow. The 'cap' domain con-
sists of a 'helical' subdomain (red) and a 'maturation' subdomain (orange). The 'excision' peptide, located in the maturation subdomain,
is shown in light blue. The side chains of the catalytic triad Serl 50, His429 and Asp372 (from right to left) are in green. Some secondary
structure elements (assigned according to DSSP [58]) are labeled. Core domain: C31, 21-27; C32, 32-39; CI33, 50-54; Ca1, 63-67;
CP4, 73-75; C35, 82-84; CP6, 94-98; Ca2, 118-135; C37, 144-149; Ca3, 152-163; C8, 171-177; Ca4, 307-313; Ca5, 316-321;
Ca6, 336-341; Ca7, 350-359; C9, 363-369; Ca8, 377-386; C310, 391-401; Cl 11, 407-416; C312, 419-424; Ca9, 431-434;
Ca10, 436-447. Cap domain: Hal, 183-196; Ha2, 202-212; Ha3, 226-240; Mpl1, 261-264; M32, 267-270; Mal, 290-293; M[3,
296-299. Note that for monomer 2 the secondary structure assignments in the cap domain are slightly different from those in monomer
1. Residues in M1l are in a region of poor density and Mal is an extended coil. See also text. (b) Stereo diagram of the Ca trace of the
HPP monomer 1 with numbering of selected residues. (Figure generated using MOLSCRIPT 159].)
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There appear to be four disulfide bridges per monomer:
Cys60-Cys334, Cys253-Cys303, Cys212-Cys228 and
Cys213-Cys218. The first two disulfide bridges connect
secondary structure elements forming the active-site
cleft. The last two disulfide bridges play a critical role in
keeping the helices Hao2 and Ha3 in the helical sub-
domain together (Fig. 2). A type II' turn is observed
between residues 214 and 217. The only free cysteine
(Cys375) is located in the active-site cleft. There is one
cis-proline (ProlOl) observed per subunit. Electron
density is clearly visible for two N-acetylglucosamine
sugar moieties at position Asn 17 and one N-acetyl-
glucosamine moiety at position Asn305 per monomer.
The sugars extend out into the solvent, making few if
any interactions with the protein surface.
The HPP precursor dimer
The physiological dimer is V-shaped, with the two
monomers related to each other by a rotation K=179.6 °.
There are major differences (i.e. greater than 0.7 A for
more than three sequential CGas) in the two crystallo-
graphically distinct monomers forming the dimer, in the
regions 211-240, 255-272, 279-296 and 404-406,
resulting in a root mean square deviation (rmsd) of 1.27 A
for 449 Ca atoms. The region 211-240, containing Ha3,
differs slightly in the two monomers by an approximate
rigid-body rotation of 2°. Residues 281-293 not only
have a different spatial conformation in the two subunits,
but also different secondary structure. In monomer 1,
residues 287-289 form a 310 helix immediately followed
by an a helix composed of residues 290-293. In
monomer 2, a 310 helix is observed for residues 285-288,
while residues 289-293 have no distinct secondary struc-
ture. If the four regions showing major deviations (67
residues) are excluded from the comparison, the two
monomers are very similar and can be superimposed with
an rmsd of 0.26 A for 383 Ca atoms.
HPP precursor dimer interface and accessible surface
The cap domain (Hoal, Ha2 and two loops) and the
core domain (Ca8, C[310 and C 11) contribute approx-
imately equally to formation of the dimer interface, as
seen in Figure 3. The helical subdomain from one
monomer packs between the core domain and the heli-
cal subdomain of the other monomer, while the matura-
tion domains are not involved in the dimer interface. A
Fig. 2. Stereoview of the disulfide bridges
Cys212-Cys228 and Cys213-Cys218 as
revealed in the SIGMAA-weighted
2mF-DF c electron-density map [50].
The map was calculated from the model
refined to 2.2 A and contoured at 1r.
(Figure drawn with 0 521.
number of residues appear to play a crucial role at the
dimer interface. Residues Tyrl96, His197 and Tyr250
interact with their counterpart from the other subunit,
while residues Phe377 and Phe412 fit in hydrophobic
pockets formed by the symmetry-related monomer. The
total solvent-accessible surface of the HPP precursor
dimer is about 34200 A2 as calculated by GRASP [35].
The dimer interface involves 1600 A2 of buried accessi-
ble surface per monomer and is approximately 60% non-
polar and 40% polar/charged [35]. Thus, the interface
buries approximately 10% of the total solvent-accessible
surface per monomer.
The surface of the HPP dimer appears to be that of a
typical globular protein, tightly packed with no large
protrusions except for part of the cap domain (M1,
MP2 and M33), and loop 402-408. The solvent-accessi-
ble surface of the HPP precursor dimer, as calculated by
GRASP [35], is 45% non-polar and 55% polar/charged.
The surface properties of the protective protein are likely
to be tailored precisely for its protective task. Unfor-
tunately, little is known about the exact composition
of the multi-enzyme complex, although stoichiometry
and binding sites for -galactosidase to HPP have been
proposed [24,36,37].
Crystal packing
Each monomer in the crystal interacts with four non-
crystallographically related monomers. The most exten-
sive contact, by far, is that generating the physiological
dimer. The other three contacts are crystal contacts
between two monomers from different dimers, and
average approximately 200-800 A2 per monomer. The
largest of these crystal contacts involves the excision pep-
tides from two monomers making intimate contact with
each other (region 265-267, 281-295 from monomer 1
with residues 281-293 from monomer 2). Together these
loops create an intermolecular buried surface of 1680 A2
for the two monomers, a surface about half the size of
the dimer interface. This large contact possibly stabilizes
an otherwise very flexible area, and may explain the good
diffraction qualities of the P2 1212 crystals (in sharp con-
trast to the five other HPP precursor crystals forms found
diffracting to 3.5 A or poorer resolution). Whether this
crystal contact reflects any physiological significance
remains to be established.
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Major differences, and comparison with the serine
carboxypeptidases
The overall fold of the monomers from HPP, CPW and
CPY is similar [16,17]. The complete core domains of
HPP and CPW superimpose with an rmsd of 1.7 A for
302 Ca atoms and have 38% sequence identity. Deleting
major deviating loops to yield only the central part of
these domains allows HPP to superimpose on CPW with
an rmsd of 1.2 A (293 equivalent Cos with 40%
sequence identity for CPW). The 271 equivalent Coas in
CPY (with 42.2% identity) superimpose on HPP with
an rmsd of 1.2 A.
Fig. 3. Schematic ribbon diagram of the HPP dimer viewed
approximately along the twofold axis. For monomer 1, the core
domain is yellow while the cap domain consists of a helical sub-
domain in red and a maturation subdomain in orange. For
monomer 2, the core domain is green, while the cap domain
consists of a dark blue helical subdomain and a light blue matu-
ration subdomain. (Figure generated using MOLSCRIPT [59].)
HPP and the hydrolase family
HPP belongs to the hydrolase fold family which includes
enzymes with different catalytic functions such as the ser-
ine carboxypeptidases [16,17], dehalogenase, various
lipases and acetylcholinesterase [18]. Although the central
core is the same (a central 13 sheet flanked by a helices on
both sides), the cap domains in this protein family are
quite diverse, both with respect to their folds as well
as their sizes (Fig. 4). HPP has one of the largest cap
domains, with 121 residues forming the three-helix
bundle of the helical subdomain and the three-stranded
3 sheet of the maturation subdomain.
The cap domain in HPP differs significantly from the
CPW and CPY counterparts. The HPP precursor struc-
ture reveals a large maturation subdomain not present in
the structures of CPW and CPY for which the structures
of the enzymatically active forms are known, but not the
precursors. All three enzymes do contain a three-helix
bundle in the cap domain (see Fig. 4), albeit with low
sequence identity in this region (-12%). Superimposing
the helical bundle in the HPP and CPW cap domains
reveals that helix Hol in HPP maintains the same gen-
eral orientation with respect to the core domain (differ-
ing by only 7.4°), but helices Ha2 and H3 have
undergone major rotations (bv K=28.5 and K= 93. 4
respectively). Given the integral role of the cap domain
in forming the dimer interface it is of interest to compare
the dimers of HPP and CPW. (The structure of CPY was
not considered because it is found as a monomer in the
crystal structure [17].)
The orientation of the monomers in forming the dimer,
differs between HPP and CPW. Superposition of the
core domain of one monomer from each dimer shows
that the second pair of monomers forming the respective
Fig. 4. Topological comparison of six
members of the hydrolase fold family. The
arrangement of structural elements in the
central core domain (in green and yellow)
of the different proteins is generally simi-
lar. The cap domains (in red) vary greatly.
The secondary structure assignments were
generated with , using structures taken
from the Brookhaven Protein Data Bank
(PDB). The following structures are shown
(references and PDB entry codes are given
in parentheses): (a) the HPP precursor
(this work), cap domain consists of two
subdomains one -helical and the other
mainly p sheet; (b) CPW (3SC2; [16]), cap
domain helical; (c) CPY (1YSC; [17]), cap
domain helical; (d) dehalogenase (2HAD;
[451), cap domain helical but quite differ-
ent from the serine carboxypeptidases;
(e) lipase from Pseudomonas glumae
(1TAH; [611), cap domain mixed helical
and 3 strands; (f) acetylcholinesterase
(1ACE; [441), cap domain large and pre-
dominantly helical. (Figure generated
using MOLSCRIPT [59].)
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dimers differ by a remarkable 150 in orientation (Fig. 5).
Thus, it appears that the extensive differences in the cap
domains, in particular the difference in orientation of the
helical bundles with respect to the core domain, lead to a
different arrangement of the subunits in the dimers of
HPP and CPW.
Catalytic triad and enzymatic mechanism
Our structure shows that the precursor HPP has all the
elements proposed for the enzymatic machinery of the
serine carboxypeptidases [16,17], and is now the third
member of this family to have its structure elucidated.
The catalytic triad in the active site of HPP is formed by
residues Ser150, His429 and Asp372 in agreement with
the proposal by Galjart et al. [12]. The Oy of Ser150
forms a good hydrogen bond with the Nel of His429
with an N...O distance of 2.8 A. The N81 of His429 is
2.7 A removed from the 082 and 3.3 A from the 081 of
Asp372. The carboxylate of Asp372 and the imidazole of
His429 in HPP are non-planar, making an angle of
approximately 600 between the imidazole and the car-
boxylate. Two backbone amides appear to orient the car-
boxylate group of Asp372: the N of Ala374 is 3.0 A from
081 of Asp372 and the N of Cys375 is 2.9 A from 082
of Asp372. The oxyanion hole proposed to stabilize the
negatively charged tetrahedral intermediate in serine car-
boxypeptidases [16] is formed in HPP by the backbone
amides of Gly57 and Tyrl51. The 32 atoms of the cat-
alytic triad residues plus the oxyanion hole amides from
HPP, CPY and CPW superimpose with an rmsd of
0.4 A (see Table 1).
In HPP, a pair of glutamic acid residues (Glu69 and
Glu149) is positioned near the catalytic triad, with their
carboxylate groups interacting with each other. The car-
boxylate groups are located at approximately 8 A from
the Oy of Serl50, and lie at the bottom of the active site.
The two carboxylates interact with each other via hydro-
gen bonds. In addition, an asparagine (Asn55) is oriented
such that it forms a hydrogen bond to each of the two
carboxylate groups of the glutamic acid pair, at an N82
(Asn) to Oel/OE2 (Glu) distance of 3.0 A and 3.6 A
respectively. These three residues are conserved between
HPP, CPW and CPY and have been implicated in regu-
lating the low pH optimum for the carboxypeptidase
activity found in the serine carboxypeptidases [16].
Fig. 5. Superposition of the Ca traces of HPP (mauve) and CPW
(cyan) dimers based on alignment of the core domains from the
subunits shown on the right-hand side. Notice the remarkable
difference in mutual orientation (of 15° ) of the two subunits on
the left-hand side of the two dimers. (Figure drawn with O [52].)
Biochemical data have suggested that a functional group
with an apparent pKa value of pH 5.5 binds the C-termi-
nal carboxylate group of peptide substrates and is respon-
sible for the observed pH optimum (reviewed in [19,20]).
Liao et al. [16] have suggested that at pH 5.5 or below,
one or both glutamic acid residues must be uncharged,
while at higher pH deprotonation of one or both of the
carboxylates may result in unfavorable electrostatic inter-
actions. This would disturb the hydrogen-bonding pat-
tern or result in structural perturbations causing the
observed increase in Km for peptide substrates. The
Table 1. Superposition of the proposed catalytic machinery of the
serine carboxypeptidases with known three-dimensional structures.
HPP CPW AHPP- CPY AHPP-
CPW CPY
Catalytic
triad Serl50 N Ser146 0.3 Ser146 0.4
Ca 0.4 0.5
C 0.3 0.4
O 0.3 0.4
C13 0.9 1.1
Oy 1.5 0.9
His429 N His397 0.2 His397 0.4
Ca 0.3 0.4
C 0.3 0.5
O 0.5 0.6
C3 0.3 0.6
Cy 0.3 0.5
C82 0.7 0.5
CE1 0.4 0.5
N81 0.3 0.4
NE2 0.7 0.5
Asp372 N Asp338 0.2 Asp338 0.2
Ca 0.1 0.1
C 0.1 0.1
0 0.2 0.1
C3 0.3 0.2
Cy 0.2 0.1
061 0.2 0.3
082 0.4 0.1
Oxyanion
hole G157 N G1353 0.1 Gl33 0.5
Ca 0.2 0.4
C 0.1 0.4
O 0.3 0.8
Tyrl51 N Tyrl47 0.3 Tyr147 0.2
Ca 0.2 0.1
C 0.3 0.2
O 0.5 0.2
pH
regulators* Asn55 Asn51 0.2 Asn51 0.2
Glu69 Glu65 0.3 Glu65 0.7
Glu149 Glu145 0.4 Glu145 0.4
The residues forming the proposed catalytic machinery are strictly
conserved between the three serine carboxypeptidases. The
deviation in distance between the atoms from HPP and the
equivalent atoms in CPW or CPY after superposition is given in A.
*Averaged over all atoms.
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CPW and CPY structures have been determined at
pH 5.7 and at pH 6.5-7.0 respectively, while the struc-
ture of HPP has been determined at pH 8. As the
arrangement of the Glu-Glu-Asn cluster in all three
structures is essentially identical (see Table 1), our struc-
ture seems to rule out any significant conformational
changes of these residues at up to 2.5 pH units above that
optimal for carboxypeptidase activity. The high degree of
conformational conservation, however, does indicate a
role in some characteristic shared by all three enzymes.
From our comparison it is clear that the enzymatic
machinery in the inactive precursor HPP has a very high
degree of structural similarity to that found in the struc-
tures of the fully active CPW and CPY enzymes.
Active site and substrate specificity
HPP has a substrate preference for hydrophobic residues
in the P1 and/or P1' binding pockets [29]. In CPW, the
P1' pocket was identified as consisting of two tyrosine
residues (Tyr60 and Tyr239) which form a long channel,
capped by two acidic residues (Glu272 and Glu398) [16],
explaining the high preference of this enzyme for argi-
nine and lysine as the leaving group [38]. In HPP, the
analogous residues are Tyr247 and Asp64, forming the
sides of the P1' pocket with Met430 and Thr304 at the
far end. However, a more detailed description of the P1,
P2 and P1' binding pockets and a better understanding of
their observed biochemical preferences requires structural
information on the mature form of HPP.
Inactivation mechanism of the precursor form
The active-site cleft in the precursor is blocked by
numerous residues from the maturation subdomain. The
catalytic triad is rendered solvent inaccessible by residues
Asn275, Ile276 and Phe277. These residues are part of
the polypeptide Asp272-Phe277 which we call the
'blocking' peptide. This peptide is held down predomi-
nantly by hydrophobic contacts of Leu273, Ile276 and
Phe277 to the core domain residues Gly57, Cys60,
Leul80, Leul90, Va1191, Leu232, Val235, Ala236,
Ile246, Leu280, Leu282, Met299 and Ala374 (Fig 6).
Residue Asn275 of the blocking peptide appears to fill
what might be part of the P1 binding pocket in the
mature form. The blocking peptide does not assume a
conformation that a productive peptide substrate would
adopt. It is carefully positioned to avoid being cleaved by
the nearby catalytic residues. In particular, Gly274 (with
Ramachandran angles 0=66 ° and =28) appears critical
in allowing the polypeptide chain to adopt a conforma-
tion in which its main chain is at a safe distance from the
catalytic triad. The P1' binding pocket seems to be com-
pletely filled by Pro301 interacting with Thr304, Tyr247,
Cys60 and Cys334. Thus, substrate binding is prevented
in the precursor form by the inaccessibility of the sub-
strate-binding pockets.
In our crystal structure, the excision peptide (residues
285-298) in both monomers extends out from the pro-
tein surface rendering it accessible to solvent and pro-
teases. Of the three cleavage sites thought to be utilized
upon trypsin digestion, Arg284 and Arg292 are particu-
larly well exposed. The main-chain atoms of Arg298 are
less accessible, being sandwiched between the strand
MP32 and a loop N-terminal to helix Cot6, while the
side-chain atoms of Arg298 are only partially solvent
accessible due to a salt bridge with Glu264.
Proposed maturation event and extent of conformational
rearrangement
Our structure reveals that the inactivation mechanism of
HPP is based on blocking of the active site, not upon
conformational changes of the residues involved in catal-
ysis or transition-state stabilization. The excision peptide
itself does not bind in the active-site cleft. Hence remov-
ing it is not in itself sufficient to allow solvent or substrate
access to the active site and maturation must be accom-
panied by conformational changes.
Based on the HPP precursor structure and the compari-
son with CPW and CPY, it is proposed that upon matu-
ration a region comprising approximately residues
254-284 rearranges to free the P1 and P2 binding sites,
while the residues 299-302 rearrange to free the P1'
binding pocket (see Fig. 7). The linker connecting these
two segments of polypeptide chain is the 14 amino acid
Fig. 6. Close-up of the 'blocking' pep-
tide (residues 272-277), shown in thick
lines bound in the active site, rendering
the catalytic triad solvent inaccessible.
Side chains are shown for residues mak-
ing extensive contacts with the blocking
peptide. The catalytic triad is shown in
gray. (Figure drawn with O [52].)
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Fig. 7. Stereoview of the elements pro-
posed to be involved in the activation
mechanism of the precursor form of
HPP. The Ca trace of the maturation
subdomain is shown in yellow, except
for the excision peptide shown in light
blue. Relevant side chains are depicted
and labeled. The solvent-accessible sur-
face was calculated and visualized
together with the atomic coordinates by
Insight II (Biosym Technologies Inc., San
Diego, CA).
excision peptide Met285-Arg298. The number of
residues involved in these rearrangements is likely to be
limited by the Cys253-Cys303 disulfide bridge which is
conserved in the serine carboxypeptidase family. This
critical disulfide serves to keep the secondary structure
elements together at the far end of the P1' pocket.
It is not clear what creates the driving force behind the
conformational changes required to open up the active
site. No biochemical studies have been performed to
investigate the extent to which a pH shift and/or the
cleavage event(s) trigger conformational rearrangement
during the maturation event. The structure of the HPP
precursor does yield some hints. A rectangular array of
salt bridges is observed between Arg262, Asp300, Glu264
and Arg298, four residues located on strands M31 and
MP3 of the mixed 13 sheet found in the maturation sub-
domain. This cluster of residues is strategically positioned
at the base of the excision peptide, close the core domain
and 'shields' the mixed 3 sheet via side-chain interactions
(see Fig. 7). These residues are strictly conserved among
the human, mouse and chicken protective proteins [27].
A similar double salt bridge has been observed in
pepsinogen, an aspartic protease zymogen, between the
proenzyme segment (Arg8P) and the enzyme (Arg308,
Glu13, Asp304) and has been proposed to function as a
pH-dependent trigger for the removal of the proenzyme
segment [39]. In the HPP precursor a similar scenario
might be envisaged, although the lack of biochemical
data makes this purely speculative. Upon arrival in the
endosome/lysosome, the charge cluster would be
affected by a shift from neutral to acidic pH. Protonation
of either the asparagine or the glutamic acid residue or
both, would result in unfavorable electrostatic interac-
tions and destabilization of this charge cluster. This might
in turn promote partial unfolding of the maturation sub-
domain, allowing easier access to additional potential
cleavage sites, or it might stimulate removal of the block-
ing peptide which fills the active site in the precursor.
The maturation mechanism for HPP appears to be novel
among those proteases for which the three-dimensional
structure of the zymogen is known. To our knowledge
three different mechanisms have been elucidated so far, for
the conversion of a protease zymogen to a mature enzyme.
First, in the serine protease family, activation of chymo-
trypsinogen and trypsinogen has been shown to entail
multiple cleavage events of the polypeptide chain allow-
ing small rearrangements in the enzymatic machinery to
occur (involving the oxyanion hole, the S1 primary
binding site and formation of an internal salt bridge in
the active site, as reviewed in [40]). Thus, activation
involves structural changes to reposition selected ele-
ments of the enzymatic machinery into a catalytically
competent conformation.
In the second mechanism, found in the zinc-containing
metalloprotease family, it has been shown for pro-
carboxypeptidases A and B that an extensive N-terminal
domain blocks the active site [41]. Removal of this domain
by cleavage of a single peptide bond renders the active site
accessible, and no further rearrangements are needed to
obtain activity. Thus, the catalytic machinery in the zymo-
gen is already in a conformation suitable for catalysis and
inactivation results from physical obstruction by residues
subsequently removed during the activation process.
A third activation mechanism has been revealed in the
aspartic proteases by comparing the structures of pepsino-
gen and pepsin [39]. An N-terminal domain, held down
by ionic interactions, blocks the active site. Upon a shift
to low pH, this domain is thought to (partially) dislocate
from the active site, undergoing conformational changes
that allow it to be autocatalytically removed [39]. Hence
a conformational change precedes (autocatalytic) cleavage
and the residues involved in blocking the active site are
removed to generate the mature enzyme.
In HPP a fourth mechanism for protease zymogen acti-
vation is revealed (see Fig. 8). In this case, the catalytic
triad in the precursor form is in a catalytically competent
conformation. Enzymatic activity is prevented by the
blocking peptide. The blocking peptide is, however, not
the same as the excision peptide. This leads to a distinct
difference from other maturation mechanisms. After dis-
appearance of the excision peptide, up to 35 residues fill-
ing the active-site cleft in the HPP precursor must
rearrange to render the catalytic triad solvent accessible,
but these residues do not get cleaved off. Removal of the
excision peptide, and possibly a shift to lower pH in the
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endosome/lysosome, appears to be a trigger for this
event. Surprisingly, the maturation mechanism of the ser-
ine carboxypeptidases HPP, CPW and CPY may differ
from each other as well. This is clearest for CPY, in
which a 91-residue polypeptide is cleaved off the N ter-
minus to convert the zymogen to an active enzyme [42],
as opposed to the excision of a peptide from within the
zymogen generating a two-chain active form as is the
case for HPP and CPW [14,19].
Considering the hydrolase fold family as a whole, the
catalytic triad is housed in the core domain and the vari-
ous cap domains attenuate the biological function by
influencing entirely different properties such as: enzyme
kinetics (exemplified by the interfacial activation of
lipases [43]); substrate channeling (as proposed for acetyl-
cholinesterase [44]); substrate recognition (as proposed by
Franken et al. [45] for dehalogenase and by Endrizzi et al.
[17] for CPY and CPW); and enzyme inactivation (as
shown here for HPP). Nature seems to have employed a
common theme for totally different purposes.
Biological implications
The lysosomal storage disease, galactosialidosis,
has been linked to a deficiency in the human 'pro-
tective protein' (HPP), believed to be identical to
cathepsin A. HPP is thought to form a multi-
enzyme complex with PI-galactosidase and neu-
raminidase in the lysosomes, protecting these two
glycosidases from degradation, in their harsh
acidic and proteases-rich environment. The struc-
tural basis of the mechanism by which this pro-
tection is achieved is unknown.
Enzymatically, HPP is classified as a serine car-
boxypeptidase. It shares 30% sequence identity
with the wheat and yeast serine carboxypeptidases
(CPW and CPY). In its precursor form, HPP is
inactive, but upon maturation, entailing removal
of a 2 kDa 'excision' peptide, carboxypeptidase
3
(mature)
Fig. 8. Schematic representation of the
proposed activation of HPP. The active-
site cleft is formed by the core domain
and the helical subdomain (indicated
as a). The maturation subdomain (m)
contains the residues which block the
active-site cleft rendering the precursor
enzymatically inactive (structure 1). In the
acidic endosome/lysosome, the precursor
undergoes activation. In activation path-
way 2a, conformational rearrangements
induced by low pH might render the exci-
sion peptide more accessible to proteases
as a first step, followed by cleavage of the
polypeptide chain removing the excision
peptide. Alternatively, in pathway 2b,
proteolytic cleavage of the excision pep-
tide might trigger the total rearrangement,
removing the blocking peptide from the
active site and thus generating the fully
active enzyme (structure 3).
activity is released [14]. We have solved the struc-
ture of the precursor form of HPP to 2.2 A at
pH 8, and found it to be a dimer. The precursor
form of HPP is of interest as it is the only form of
the enzyme which is secreted by cells and can be
taken up by others via endocytosis. This latter
property is of potential therapeutic significance
for the treatment of galactosialidosis.
The HPP monomer can be divided into a 'core'
domain housing the catalytic triad and a 'cap'
domain consisting of a 'helical' subdomain and a
'maturation' subdomain. The core domains of
HPP, CPW [16] and CPY [17] have very similar
folds that classify them as members of the hydro-
lase fold family [18]. However, significant differ-
ences are observed in the arrangement of the
structural elements in the HPP helical subdomain
as compared with its counterpart in CPW and
CPY. Although HPP and CPW both form dimers,
comparing the configuration of the subunits that
generate the dimer in each enzyme reveals a sig-
nificant (150) rotational difference, which would
have been hard to predict by homology modelling.
The precursor structure enables us to propose an
inactivation mechanism that has not been seen
before in any of the other known zymogen struc-
tures of proteases. The catalytic triad of HPP
seems to have an arrangement poised for catalysis.
However, the triad and substrate-binding site are
rendered inaccessible to solvent and substrate by
residues from the maturation subdomain binding
in the active-site cleft. Most of these residues are
found in a strand called the 'blocking' peptide
which does not overlap with the 2 kDa excision
peptide. After removal of the excision peptide, up
to 35 additional residues must rearrange in order to
unblock the active-site cleft. It is not clear what
the driving force is for the conformational changes.
A strategically positioned pair of salt bridges,
-1101,
-<, __
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comprising Arg262, Arg298, Glu264 and Asp300 at
the base of the excision peptide, may become
destabilized at low pH, unraveling this region of
the structure, allowing easier access to cleavage
sites and/or promoting the rearrangement event.
A number of research groups are currently
involved in designing enzyme and gene therapy
procedures for several lysosomal storage diseases.
Insight into the three-dimensional structure, pro-
tein functioning and stability of HPP, the first
enzyme associated with a lysosomal storage dis-
ease for which a structure has been determined,
may prove useful in future designs of an adequate
therapy procedure for galactosialidosis. Informa-
tion from the three-dimensional structure of HPP,
might also aid in designing an engineered form of
HPP with increased stability and a longer half-life.
Material and methods
Purification and crystallization
The HPP precursor was over-expressed in a baculovirus system
[14]. The precursor could be purified to better than 95%
homogeneity using ion-exchange chromatography starting
from a partially pure preparation containing both the precursor
and the cleaved forms. Extensive screening yielded various
crystal forms (Rudenko et al., unpublished data). The crystals
suitable for data collection and the structure determination
were grown in polyethylene glycol 8000 at pH 8.0-8.3 in
space group P21212 with cell dimensions a=115.04 A,
b=148.11 A, c=80.97 A.
Data collection, data processing and reduction
Diffraction data were collected at the Stanford Synchrotron
Radiation Laboratories to 2.0 A at -1780C on a MAR imaging
plate at a wavelength of 1.08 A on beamline 7-1. The data
were processed and reduced with the CCP4 suite [46] using
the programs MOSFLM version 5.2, REFIX [47],
ROTAVATA, AGROVATA and TRUNCATE. The data set
contains 436709 reflections between 32.3 A and 2.2 A,
reducing to 67740 unique reflections. The I/a for the highest
resolution shell of the data used in the structure determination
(2.26-2.20 A) is 5.7. The data is 95.7% complete to 2.2 A with
an Rsym of 5.1%. The Vm [48] is 3.2 A3 Da-' for two
monomers in the asymmetric unit, corresponding to a solvent
content of 62%.
Molecular replacement
A multi-alanine search model for a monomer was constructed
from the atomic coordinates for the wheat serine carboxypepti-
dase [16], aided by sequence alignment made by the GCG
program PILEUP (Genetics Computer Group, Madison, Wis-
consin). Residues identical between the two proteins were left
in the model, residues with the same sized side chain were left
unaltered and the rest of the residues were truncated to ala-
nines. The search model contained 331 residues. Data between
4-8 A were used for the rotation function, Patterson correla-
tion refinement and translation function calculations carried
out by X-PLOR [49]. A Patterson cutoff vector of 21 A was
used. Two orientations were found for the monomer and the
individual translation functions gave a clear position for each
orientation with peaks 7.7cr and 8.8ar above the mean. A com-
bined translation function placed the two monomers relative to
the same crystallographic origin, and yielded a packing in
which the two monomers formed a physiological dimer as
judged by their extensive interactions. This initial structure
solution gave an R factor of 51.5% for data between 6 A and
4.5 A, which decreased to 49.2% after rigid-body refinement.
Density modification and map interpretation
Electron-density maps were calculated using the programs
from the CCP4 computing package [46]. In the initial
SIGMAA-weighted 2mFo-DFc map [50] reasonable density
appeared to be present for 294 residues. Therefore, 158
residues, or 35%, were still missing per monomer. By using
cycles of twofold averaging with the program RAVE [51] and
gradual model expansion, 148 residues per monomer could be
added. For map visualization and model building the program
O [52] was used on a Silicon Graphics workstation.
Refinement and model validation and analysis
Rigid-body and positional refinement were carried out using
the program X-PLOR [49] with the stereochemical parameters
of Engh and Huber [53]. At this stage the model was still miss-
ing 20 residues (10 per subunit). Eighteen of these residues
could gradually be incorporated in the model during additional
cycles of positional refinement and model building. 1 he rctine
ment procedure started out using data from 8-3.0 A and was
gradually extended to include data from 8-2.2 A. H-vlues for
individual atoms were refined once data between 2.4 A and
2.2 A had been added. The program ARP [54] was used to add
crystallographic waters and as a tool to check for bad areas in
the model. The programs PROCHECK [55], WHATIF [56]
and PROFILE 3D [57], as well as the geometrical analysis gen-
erated by X-PLOR have been used to check the structure for
errors. For the final refinement cycle, 10% of the weakest data
were rejected using an I Fobs I/or cutoff and anisotropic scaling
was applied between Fobs and Fcalc to compensate for a rapid
fall-off in intensity along the crystallographic a axis. The R fac-
tor for the current model is 21.3% for data between 8-2.2 A;
the Rfree is 26.8% (see Table 2). The estimated rms coordinate
error according to SIGMAA [50] is 0.282 A. The rmsds from
ideality are 0.012 A for bond lengths and 1.72 ° for bond
angles. The current model consists of 902 residues out of a total
of 904 for the dimer, numbered 1-452 for monomer 1 and
monomer 2. In addition, 296 waters and six N-acetyl-
glucosamine moieties have been incorporated. The electron
density for residues 259 and 260 from monomer 2 is not well
Table 2. Data statistics for refinement.
Resolution Rcryst Completeness Cumulative
(A) (%) (%) completeness (%)
8.00-4.21 22.0 93.5 93.5
4.21-3.42 19.3 92.7 93.1
3.42-3.02 20.6 88.6 91.6
3.02-2.75 21.3 84.2 89.8
2.75-2.56 22.0 78.6 87.6
2.56-2.42 22.2 73.1 85.2
2.42-2.30 22.7 64.6 82.3
2.30-2.20 24.0 56.9 79.2
8.00-2.20 21.3 82.9
Rcryst=; II Fob,(h)- I Fcac(h)l I/ Fobs(H) I . Figures for the
completeness of data included in the refinement are given
after rejecting 10% of the weakest reflections using an
|Fobs l/ cutoff for data between 8 A and 2.2 and
partitioning 5% of the data in a test set for monitoring the Rfree.
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defined, and these residues have not been included in the
model. In total, 14 side chains are not visible and an alanine
side chain has been incorporated into the model. For monomer
1, these residues are: Lysl5, Lys27, Glu46, Phe113, Glu326
and Val393. For monomer 2, these residues are: Glu46,
Gln215, Lys217, Phe261, Tyr263, Lys265, Lys296 and
Glu326. The average individual B-factor for main-chain atoms
is 16.6 A2 and for side-chain atoms 18.3 A2. The program
GRASP [35] was used for the molecular surface analyses and
the program SUPPOS (Dijkstra et al., unpublished program)
was used for all the least-square superpositions of various
models and parts of the models.
Coordinates have been forwarded to the Brookhaven Protein
Data Bank.
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